US FDA Nod for Indian Drug Maker Jubilant's Anti-Infection Drug Levofloxacin

The company, which had 806 filings for formulations till March 31, 2015, got approval for 368 of them from various regions worldwide, including 72 from FDA.

Leading Indian drug maker Jubilant Life Sciences has announced that it had received approval of the US Food and Drug Administration (FDA) for its tablets used in treating adults for various infections.

The company said, "Levofloxacin tablets are the generic version of Levaquin of Ortho-McNeil, used for treating infections such as pneumonia, sinusitis, bronchitis, prostatitis, urinary tract and inhalational anthrax."

The market size for Levofloxacin is estimated to be $28 million (Rs.179 crore) per annum.

The company, which had 806 filings for formulations till March 31, 2015, got approval for 368 of them from various regions worldwide, including 72 from FDA.

The Noida-based integrated drug maker, Jubilant, manufactures and supplies active pharmaceutical ingredients, solid dosage formulations, specialty pharmaceuticals and life science ingredients. The firm also provides services in contract manufacturing and drug discovery solutions to global firms from its 10 production units in India, Canada and the US.

Antibiotics can Cause Severe Liver Injury
In older people, common antibiotics moxifloxacin and levofloxacin are associated with an increased risk of severe liver injury, states study published in CMAJ.

Source-IANS

Drug of Indian Manufacturer Tentatively Approved by FDA
The FDA in the US has tentatively approved Aurobindo Pharma to manufacture and market levofloxacin tablets in the American market.